- Home
- AKRO
as 07-26-2024 4:00pm EST
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 1.9B | IPO Year: | 2019 |
| Target Price: | $41.43 | AVG Volume (30 days): | 890.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.25 - $53.77 | Next Earning Date: | 08-09-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Akero Therapeutics Inc. (AKRO)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| White William Richard | AKRO | Chief Financial Officer | Jul 16 '24 | Sell | $28.05 | 5,008 | $140,449.36 | 41,791 | SEC Form 4 |
| White William Richard | AKRO | Chief Financial Officer | Jul 16 '24 | Sell | $28.05 | 29,803 | $835,825.14 | 46,799 | SEC Form 4 |
| Young Jonathan | AKRO | Chief Operating Officer | Jun 28 '24 | Sell | $23.40 | 5,000 | $117,020.00 | 246,854 | SEC Form 4 |
| Rolph Timothy | AKRO | Chief Scientific Officer | Jun 11 '24 | Sell | $22.64 | 2,380 | $53,885.58 | 180,178 | SEC Form 4 |
| White William Richard | AKRO | Chief Financial Officer | Jun 11 '24 | Sell | $22.64 | 2,831 | $64,093.84 | 46,799 | SEC Form 4 |
| Yale Catriona | AKRO | Chief Development Officer | Jun 11 '24 | Sell | $22.64 | 2,825 | $63,960.83 | 74,867 | SEC Form 4 |
| Lamy Patrick | AKRO | Senior VP, Commercial Strategy | Jun 11 '24 | Sell | $22.64 | 569 | $12,882.73 | 18,562 | SEC Form 4 |
| Young Jonathan | AKRO | Chief Operating Officer | Jun 11 '24 | Sell | $22.64 | 2,516 | $56,964.76 | 250,790 | SEC Form 4 |
| Young Jonathan | AKRO | Chief Operating Officer | Jun 3 '24 | Sell | $19.29 | 5,000 | $96,440.00 | 253,306 | SEC Form 4 |
| Young Jonathan | AKRO | Chief Operating Officer | May 1 '24 | Sell | $20.15 | 5,000 | $100,749.50 | 258,306 | SEC Form 4 |
| Young Jonathan | AKRO | Chief Operating Officer | Apr 1 '24 | Sell | $25.03 | 400 | $10,010.00 | 263,306 | SEC Form 4 |
| Young Jonathan | AKRO | Chief Operating Officer | Apr 1 '24 | Sell | $24.33 | 4,600 | $111,902.82 | 263,706 | SEC Form 4 |
| Yale Catriona | AKRO | Chief Development Officer | Mar 13 '24 | Sell | $28.33 | 723 | $20,482.59 | 77,692 | SEC Form 4 |
| Young Jonathan | AKRO | Chief Operating Officer | Mar 13 '24 | Sell | $28.33 | 651 | $18,442.83 | 268,306 | SEC Form 4 |
| White William Richard | AKRO | Chief Financial Officer | Mar 13 '24 | Sell | $28.33 | 724 | $20,510.92 | 49,630 | SEC Form 4 |
| Cheng Andrew | AKRO | President and CEO | Mar 13 '24 | Sell | $28.33 | 1,969 | $55,781.77 | 589,447 | SEC Form 4 |
| Cheng Andrew | AKRO | President and CEO | Mar 4 '24 | Sell | $31.40 | 35,827 | $1,124,974.97 | 630,589 | SEC Form 4 |
| Cheng Andrew | AKRO | President and CEO | Mar 4 '24 | Sell | $32.28 | 6,770 | $218,537.63 | 623,819 | SEC Form 4 |
| Cheng Andrew | AKRO | President and CEO | Mar 4 '24 | Sell | $33.83 | 9,614 | $325,266.62 | 614,205 | SEC Form 4 |
| Cheng Andrew | AKRO | President and CEO | Mar 4 '24 | Sell | $34.63 | 14,680 | $508,372.80 | 599,525 | SEC Form 4 |
| Cheng Andrew | AKRO | President and CEO | Mar 4 '24 | Sell | $35.49 | 7,995 | $283,775.33 | 591,530 | SEC Form 4 |
| Cheng Andrew | AKRO | President and CEO | Mar 4 '24 | Sell | $36.28 | 114 | $4,135.92 | 591,416 | SEC Form 4 |
| Yale Catriona | AKRO | Chief Development Officer | Mar 4 '24 | Sell | $35.49 | 20,646 | $732,726.54 | 78,415 | SEC Form 4 |
| Young Jonathan | AKRO | Chief Operating Officer | Dec 27 '23 | Sell | $24.00 | 5,414 | $129,936.00 | 185,131 | SEC Form 4 |
| Young Jonathan | AKRO | Chief Operating Officer | Dec 14 '23 | Sell | $20.76 | 543 | $11,272.68 | 185,131 | SEC Form 4 |
Latest Akero Therapeutics Inc. News
AKRO Breaking Stock News: Dive into AKRO Ticker-Specific Updates for Smart Investing
MT Newswires
13 hours ago
Akero Therapeutics Insider Sold Shares Worth $4,381,867, According to a Recent SEC Filing
Zacks
10 days ago
Akero Therapeutics (AKRO) Moves to Buy: Rationale Behind the Upgrade
MT Newswires
2 months ago
Wolfe Research Initiates Coverage on Akero Therapeutics With Outperform Rating, $40 Price Target
GlobeNewswire
2 months ago
Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
GlobeNewswire
2 months ago
Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024
Zacks
2 months ago
Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results
GlobeNewswire
2 months ago
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
MT Newswires
2 months ago
Evercore ISI Adjusts Price Target on Akero Therapeutics to $38 From $50, Maintains Outperform Rating
Compare AKRO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AKRO Akero Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.